k4dd.eu
Mission: K4DD
http://www.k4dd.eu/about-k4dd/mission.html
K4DD 2017 Berlin Meeting. Linking to the clinic. K4DD 2017 Berlin Meeting. To enable the adoption of drug-target binding kinetics analysis in the drug discovery decision-making process, and thereby contribute to the development of a new generation of improved medicinal products. Early and improved prediction of the efficacy and safety of a candidate drug in the clinic. To complete its mission K4DD has set three main objectives:.
k4dd.eu
K4DD member organizes EFMC course: K4DD
http://www.k4dd.eu/about-k4dd/news/news-detail/item/k4dd-member-organizes-efmc-course.html
K4DD 2017 Berlin Meeting. Linking to the clinic. K4DD 2017 Berlin Meeting. K4DD member organizes EFMC course. K4DD members Ad IJzerman and Laura Heitman will be hosting an EFMC short course centered on drug-target binding kinetics. The, A matter of time:. A kinetic perspective on drug-target interactions. For more information please visit: www.efmcshortcourses.org.
k4dd.eu
Realizing high-throughput: K4DD
http://www.k4dd.eu/k4dd-strategy/realizing-high-throughput.html
K4DD 2017 Berlin Meeting. Linking to the clinic. Linking to the clinic. Workpackage 2: Getting up to speed with drug-target kinetics: Development of robust off-the-shelf assays. K4DD combines both the expertise on drug targets as well as technologies to achieve robust assays for kinetic binding rates. Of a drug kinetic signature. Optimization of techniques by increasing the throughput [ D.Guo, 2012. Adapting techniques to difficult (e.g. instable) protein targets [ I. Navratilova, 2005. Is already ongoin...
k4dd.eu
K4DD strategy: K4DD
http://www.k4dd.eu/k4dd-strategy.html
K4DD 2017 Berlin Meeting. Linking to the clinic. Linking to the clinic. How is K4DD addressing the issue? K4DD brings together a range of world class scientists within Europe who will jointly address the issues that hinder the routine study of drug-target binding kinetics. The researchers within the K4DD project are passionate about enhancing understanding and awareness of the underlying principles of drug-target binding kinetics and they will work hard to achieve this.
k4dd.eu
About K4DD: K4DD
http://www.k4dd.eu/about-k4dd.html
K4DD 2017 Berlin Meeting. Linking to the clinic. K4DD 2017 Berlin Meeting. The 5-year K4DD program started in November 2012. K4DD is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU), resources of which are composed of a financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. PMT), which consists of the Project Coordinator (Bayer Pharma: Dr Anke Mueller-Fahrnow) and the Managing Entitity (Univ of Lei...
k4dd.eu
About Kinetics: K4DD
http://www.k4dd.eu/about-kinetics.html
K4DD 2017 Berlin Meeting. Linking to the clinic. Example of the role of binding kinetics in drug. Desloratidine is a Histamine H1 receptor antagonist approved for the treatment of allergy (e.g. hay fever). In retrospect it was shown that the long-lasting effect of desloratidine is the result of a long receptor residence time. An additional advantage is that the drug molecule does not cause drowsiness because it does not readily enter the central nervous system.
k4dd.eu
Understanding the Interaction: K4DD
http://www.k4dd.eu/k4dd-strategy/understanding-the-interaction.html
K4DD 2017 Berlin Meeting. Linking to the clinic. Linking to the clinic. Workpackage 1: Drug-target binding kinetics: Capturing and sharing the essence of it. Understanding the interaction of small drug molecules with their protein targets represents an important predictor for the clinical success of a drug (see Why spend 21 million on studying kinetics? Such knowledge can be an important asset in developing effective treatments. Figure 1. Summary of the role of WP1 in the K4DD consortium. Within the huma...
k4dd.eu
News: K4DD
http://www.k4dd.eu/about-k4dd/news.html
K4DD 2017 Berlin Meeting. Linking to the clinic. K4DD 2017 Berlin Meeting. K4DD Scientific Meeting: "Binding kinetics: Time is of the essence". On 16-18 October, K4DD will organize an open scientific meeting. The meeting will be hosted by K4DD coordinator Bayer in Berlin, Germany. Read more. K4DD enters 2017 with the acceptance of another public private publication. K4DD pharmacologists find new ways to predict the duration of drug effects. K4DD member organizes EFMC course. With a recent publication in ...
k4dd.eu
Publications: K4DD
http://www.k4dd.eu/about-k4dd/publications.html
K4DD 2017 Berlin Meeting. Linking to the clinic. K4DD 2017 Berlin Meeting. Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics. Hothersall JD, Guo D, Sarda S, Sheppard RJ, Chen H, Keur W, Waring MJ, IJzerman AP, Hill SJ, Dale IL and Rawlins PB. Kinetic Profile of Neuropeptide Receptor Interactions. Nederpelt I, Bunnik J, IJzerman AP, and Heitman LH. Journal of Medicinal Chemistry. Guo D, Heitman LH, IJzerman AP. Trends in Pharm...
